Page 1

Verastem (NASDAQ:VSTM): will the stock rebound post Q1 earnings?

May 16, 2018


Verastem (NASDAQ:VSTM) released Q1 earnings today. The EPS was -$0.41, which was $0.02 below analysts' expectations. What is the stock price forecast now? What to analysts predict? Per Finstead Research, the average analyst price target for Verastem is $11.80. This presents a significant upside to the current price of $4.70 (visit Finstead and type "VSTM upside" or "VSTM price target").

Now, let's look at the stock sentiment. Based on the technical analysis, the short-, mid- and long-term forecast is relatively rosy.


The company claims Q1'18 was a strong quarter, highlighted by the acceptance of the duvelisib New Drug Application (NDA) by the FDA. This drug treats patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and follicular lymphoma. The upcoming FDA review decision for duvelisib is due by the end of the year, and the company is building U.S. commercial capabilities for the drug's potential product launch in 2018. Verastem is also building out a world-class commercial team, led by Joseph Lobacki, who has demonstrated success in commercializing oncology drugs. For the most recent news on Verastem, you can check Finstead VSTM news page, or visit Finstead and type "VSTM news".

Verastem (NASDAQ:VSTM): will the stock rebound post Q1 earnings?  

Finstead Bites Read our insightful, bite-sized news about the stock market. Get your investment scoop quickly and efficiently.

Verastem (NASDAQ:VSTM): will the stock rebound post Q1 earnings?  

Finstead Bites Read our insightful, bite-sized news about the stock market. Get your investment scoop quickly and efficiently.

Advertisement